Use of agonists of the dectin-1/Syk pathay as adjuvant in vivo
We have used agonists of the dectin-1/Syk pathway as adjuvants in vivo to induce CD8+ T cell responses and have data available on this. In summary, we have shown that this can result in CTL capable of destroying tumours.
data set
preclinical study dataset
T cell
CD8
Internalization of Dectin-1 terminates induction of inflammatory responses.
DC activated via dectin-1 convert Treg into IL-17 producers.
Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses.
Caetano Reis e Sousa